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Editorial
An Unbiased Scientific Record Should Be 
Everyone’s Agenda
The PLoS Medicine Editors
A
large and growing literature 
details the many ways by which 
research and the subsequent 
published record can be inappropriately 
influenced, including publication bias 
[1], outcome reporting bias [2], financial 
[3] and non-financial [4] competing 
interests, sponsors’ control of study data 
and publication [5], and restrictions on 
access to data and materials [6]. But it 
can be difficult for an editor, reading a 
submitted manuscript, to disentangle 
these many influences and to understand 
whether the work ultimately represents 
valid science.
Any journal has stories to tell of 
attempts to unduly influence the 
publication process—such as the 
author who repeatedly appeals a 
manuscript’s rejection, claiming 
the reviewers are incompetent and 
demanding evaluation by a specific 
list of preferred experts, or the 
biotech company that refuses to 
publicly deposit the microarray data 
underlying their findings. Sometimes 
distortion of the scientific record 
may be limited in scope, relating to 
just one paper. But when a single 
company funds virtually an entire 
research agenda on a particular 
topic, there is the potential for 
wider and far more damaging 
distortion. In a detailed analysis 
of documentation released as part 
of a class-action lawsuit relating to 
the drug gabapentin (Neurontin), 
Kay Dickersin has described “…a 
remarkable assemblage of evidence 
of reporting biases that amount to 
outright deception of the biomedical 
community, and suppression of 
scientific truth concerning the 
effectiveness of Neurontin for 
migraine, bipolar disorders, and 
pain…” ([7], summarized in [8]). 
Here we propose five ways in which 
authors and editors can mitigate 
the effects of biased agendas on the 
published scientific record.
1. Recognize and Declare Editorial 
Interests
Journals generally have policies 
regarding declaration of competing 
interests by authors. Similarly, editors’ 
political and scientific views, personal 
relationships, and professional and 
financial interests can all conceivably 
interfere with the objectivity of their 
decisions.
Even financial pressures on a journal 
can create conditions for possible 
editorial bias. For example, journals 
that own the copyright on the articles 
they publish, giving the journal the 
right to an exclusive reprint trade, can 
sell copies of a single drug trial report 
for hundreds of thousands of dollars. 
While journals have been reluctant to 
publicize the exact amount that they 
make from such reprint sales, a Wall
Street Journal article is illustrative of the 
amount of money that changes hands. 
The newspaper reported that the New
England Journal of Medicine sold 929,400 
reprints of a single research article [9] 
reporting the results of a clinical trial 
of the painkiller rofecoxib (Vioxx) 
[10]. These reprints were mostly sold 
to the drug’s manufacturer Merck, 
bringing in more than US$697,000 [9] 
in revenue for the journal. Editors, says 
Richard Smith, “know that publishing 
such studies is highly profitable, and 
editors are increasingly responsible 
for the budgets of their journals and 
for producing a profit for the owners” 
[11]. This responsibility, he argues, 
may provide journals with a motivation 
for preferentially publishing the 
outcomes of pharmaceutical trials 
funded by industry.
One of the many advantages of open-
access publishing is that this type of 
editorial bias is minimized. Work that 
is published in open-access journals, 
which apply licenses such as the 
Creative Commons Attribution License 
used by PLoS [12], can be freely 
reused. Journals using such licenses 
therefore have no exclusive reprint 
trade, and are protected from the 
inherent bias towards industry-funded 
pharmaceutical trials that might 
otherwise operate. 
In order to acknowledge the 
potential for editorial bias, and defend 
against it, many journals annually 
update and publish the editors’ 
competing interests (e.g., [13]). At 
PLoS Medicine, editors must recuse 
themselves from the decision-making 
process for papers in which they have 
some potential competing interest—for 
example, a personal relationship with 
the authors. 
2. Be Aware of Interests Beyond 
the Commercial
So much has been published relating 
to the damaging nature of commercial 
competing interests [3] that it is 
tempting to ignore the influence of 
non-commercial interests in research. 
Yet publications can be influenced 
by the desire to promote an idea, 
or a research program, rather than 
a commercial product. At one, very 
trivial, level, this might include a 
journal receiving repeated letters 
from the same individual, each time 
outlining their pet theory and its 
relevance to articles the journal has 
published. A trickier situation to 
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manage might involve the submission 
of an article presenting research done 
by an advocacy organization, whose 
declared political position might be 
strengthened by the study reported. 
Robust journal policies regarding 
non-commercial competing interests 
(e.g., [4]) will at least require 
declaration of any interests that might 
influence reporting or review, and 
that would be influenced—negatively 
or positively—by publication. Such 
interests might include personal 
relationships or professional 
interactions with authors, editors, or 
reviewers, and strongly held political or 
religious views that relate to the work 
under consideration. 
In publishing a research article 
on the unreliability of protocols for 
execution by lethal injection [14], 
we declared our own position in an 
accompanying editorial: “Each of the 
editors of PLoS Medicine opposes the 
death penalty. It is not our intention 
to encourage further research to 
‘improve’ lethal injection protocols” 
[15]. It therefore remains for readers 
to judge for themselves to what extent 
the underlying interests of editors as 
well as authors might have affected the 
published article. 
3. Consider Whether There Is a 
Ghost in the Machine
One of the PLoS Medicine editors 
recently handled a manuscript 
describing the burden of a disease of 
poverty. The study was designed, and 
the paper apparently written up, by 
the manufacturer of a vaccine, but 
no employees of this company were 
named in the paper; the authorship 
byline included only representatives 
of a health communications company, 
along with one individual affiliated with 
the hospitals where the work was done. 
Had the manufacturer’s employees 
been listed as authors, together with 
their contributions and competing 
interests, any role of the company in 
directing the research project would 
have been appropriately evident. 
In a debate [16] published in 
this month’s issue of PLoS Medicine,
three viewpoints lay out a variety 
of approaches for combating 
ghostwriting (ghostwriting occurs 
when individuals who have made 
a substantial contribution to the 
research project, or to writing of the 
article, are not named as authors 
[17]). All contributors to the debate 
agree on one thing: a transparent 
declaration of author contributions 
is an essential requirement. As 
part of such a transparency policy, 
editors can therefore ensure that 
the individuals responsible for 
essential roles in research (such as 
designing the project, carrying out 
analyses, and writing the paper) are 
actually named, and their roles and 
competing interests made clear in the 
publication.
4. Where’s the Spin? Remember 
the Protocol
Many journals now have policies 
requiring, or recommending, the 
submission of original protocol 
documents before papers reporting 
the results of clinical trials are peer-
reviewed [18], as well as policies 
requiring that authors adhere to 
the CONSORT guidelines for trial 
reporting [19]. The intention behind 
such policies is, firstly, to promote 
transparency, and secondly, to provide 
a mechanism to detect within-study 
selective reporting (a phenomenon 
whereby some findings are omitted 
from publications and others selected 
for inclusion or emphasis, dependent 
on the direction of their results [19]). 
In practical terms, these policies 
enable verification of the study’s 
prespecified objectives and analysis 
plan, and require clear description 
of any subsequent changes. Although 
the vast majority of authors have 
been happy to send us copies of their 
protocols, we have occasionally met 
with resistance. 
In one situation, we received a report 
of a randomized, placebo-controlled 
trial of a marketed intervention, funded 
by the manufacturer of the intervention 
being studied. On requesting the 
study protocol, we received an e-mail 
from an individual affiliated with the 
company, but who was not listed as an 
author of the paper, asking us to sign 
a confidentiality agreement barring 
us from making the protocol available 
to reviewers, and from publishing 
it as supporting material, as is our 
policy for clinical trial papers. In this 
situation, we and the reviewers would 
have been unable to properly evaluate 
the submitted report; we declined to 
consider the paper further, based on 
the journal’s policy regarding reporting 
standards for clinical trials. 
5. Anti-Spin: Consider Whether 
the Data Are Important Even If the 
Results Aren’t Exciting
The Declaration of Helsinki [20] 
emphasizes that, in rejecting unexciting 
papers, editors can contribute to a 
biased research base. The Declaration 
notes: “Authors, editors and publishers 
all have ethical obligations with 
regard to the publication of the 
results of research…. Negative and 
inconclusive as well as positive results 
should be published or otherwise 
made publicly available” [20]. Editors 
have an important role to play in 
encouraging authors to value their 
results, irrespective of the study’s 
outcome. For example, in an attempt 
to impress editors with the importance 
of a study, authors may overemphasize 
an intriguing post-hoc subgroup 
analysis, or may avoid stating that a 
well-conducted trial was inconclusive in 
its primary outcomes. Editors can help 
combat this problem by emphasizing 
to authors that their data are still 
publishable if overstated conclusions 
are appropriately toned down. Access 
to research protocols, or clinical trial 
registry records, should also help 
editors to base their decisions on the 
importance of the underlying research 
question, and not on the headline 
potential of actual results. Journals such 
as our sister journal PLoS ONE (http://
www.plosone.org/), which aims to 
publish all methodologically rigorous, 
ethically sound, and properly reported 
work, provide one way to ensure that 
journals do not become part of the 
problem of publication bias.
Peer-reviewed publication is the final, 
essential step in any research project, 
providing legitimization and credit for 
the work that has been done. It is the 
responsibility of everyone involved to 
ensure that the published record is an 
unbiased, accurate representation of 
research. We recognize that today there 
are many, and increasing, pressures 
on authors and journals to bias this 
record. If this pressure is not resisted, 
journals may increasingly become 
closer to works of fiction telling the 
stories dictated by various lobbies 
rather than works of science. We hope 
that PLoS Medicine’s efforts, and those 
of many other journals, to promote full 
transparency will ultimately lead to a 
more rigorous and unbiased knowledge 
base.  PLoS Medicine  |  www.plosmedicine.org 0121 February 2009  |  Volume 6  |  Issue 2  |  e1000038
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